New Data Show Semaglutide's Effects on Depression and Migraine

As clinical results from the European Congress on Obesity (ECO) continue to emerge, the therapeutic profile of semaglutide is expanding far beyond simple weight management, offering pharmacists new data on indications ranging from cardiovascular protection to mental health and neurology. New research presented by Novo Nordisk highlights that semaglutide (Wegovy) provides significant benefits for women’s health, specifically reducing the risk of migraines and depression while maintaining efficacy across all stages of menopause.^1,2

These findings arrive at a critical juncture for the pharmacy profession, as glucagon-like peptide-1 (GLP-1) receptor agonists have surged to represent nearly 8% of all prescriptions filled in the United States as of March 2026.³

“The GLP-1s, you can’t underrate them. That’s going to be a major metabolic shift in this country,” Christopher Shade, PhD, CEO and founder of Quicksilver Scientific, said.⁴ “There's going to be a major shift in long-term chronic illness care—things like diabetes and all the complications that come from that metabolic dysfunction are going to disappear quite a bit as a result.”

The most striking data for pharmacists involves semaglutide’s impact on quality-of-life conditions that frequently co-occur with obesity. In a large-scale real-world study of over 34,000 women, those taking semaglutide experienced a 42% to 45% lower risk of migraine starting 6 months after initiation compared to those on menopausal hormone therapy alone.¹

Furthermore, the study indicated a 25% lower risk of depression. This shift suggests that semaglutide may soon be viewed through a broader lens than its primary metabolic indications, particularly since obesity is a recognized risk factor for chronic migraine, a condition that disproportionately affects women.

Beyond neurological benefits, the clinical focus has intensified on cardiovascular outcomes and body composition. Data from the landmark SELECT (NCT03574597) trial demonstrated that perimenopausal and postmenopausal women with obesity and established heart disease saw meaningful reductions in heart attacks, strokes, and cardiovascular death.

Specifically, perimenopausal women experienced a 42% lower risk compared to placebo. For the pharmacist counseling patients on the 7.2 mg dose investigated in the STEP UP (NCT05646706) trial, the focus is shifting toward muscle health rather than just the number on the scale. Analysis showed that 84% of weight loss from semaglutide was attributed to fat mass reduction, and muscle function was preserved and muscle fat—a key marker of cardiometabolic risk—was improved.²

These clinical advancements are driving an unprecedented volume of prescriptions that is reshaping the daily operations of modern pharmacies. Between December 2025 and March 2026 alone, first-time prescriptions for antiobesity medications surged by 21.7%. This growth has been further catalyzed by the 2025 approval of an oral formulation of semaglutide, which provides an alternative to the traditional weekly injection.³

However, this surge has not been without operational hurdles, as pharmacists must navigate persistent supply chain shortages, administrative burdens related to high costs, and significant rates of prescription abandonment due to coverage restrictions.

As semaglutide gains further approvals for conditions like metabolic dysfunction-associated steatohepatitis in patients with liver scarring, its role as a multi-indication standard of care is becoming more defined. Pharmacists are now positioned as essential gatekeepers who must verify these evolving indications and manage patient expectations regarding long-term therapy.

With clinical awareness growing and obesity management guidelines evolving, the data from ECO 2026 suggests that the pharmacist's role will increasingly involve monitoring a diverse range of patient outcomes that extend well beyond glycemic control and weight loss.

“When you lay too heavily on it, people rely on [GLP-1s] as a one-hit wonder, and they're not changing their diet [or] their supplementation,” Shade said.⁴

Are you ready to elevate your pharmacy practice? Sign up today for our free Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips straight to your inbox.

REFERENCES

1. Novo Nordisk A/S: Wegovy delivered substantial weight loss in women across all menopause stages, plus heart and migraine protection, shown in new Novo Nordisk data at the European Congress on Obesity. News release. Novo Nordisk. May 12, 2026. Accessed May 12, 2026. https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916546

2. Novo Nordisk A/S: Higher dose Wegovy demonstrates nearly 28% weight loss in early responders according to new analyses presented at the European Congress on Obesity. News release. Novo Nordisk. May 12, 2026. Accessed May 12, 2026. https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916545

3. Gallagher A. GLP-1s made up 8 of every 100 prescriptions filled in March 2026. Drug Topics. May 5, 2026. Accessed May 12, 2026. https://www.drugtopics.com/view/glp-1s-made-up-eight-of-every-100-prescriptions-filled-in-march-2026

4. Nowosielski B, Shade C. Q&A: Understanding the Pharmaceutical Community’s Attention on Peptides. Drug Topics. April 26, 2026. Accessed May 12, 2026. https://www.drugtopics.com/view/understanding-the-pharmaceutical-community-s-attention-on-peptides